← The Wire
GNLXNasdaq
GENELUX Corp
Pharmaceutical Preparations · DE · CIK 1231457
GENELUX Corp develops next-generation oncolytic viral immunotherapies for aggressive and difficult-to-treat cancers
$133M
Market cap
$2.90
Last close
+1.1%
1D
-0.7%
5D
200K
Volume
Price · last 39 sessions+1.8%
May 4L $2.77 · H $3.19Jun 29
74
Total filings
Jun 22, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 22, 202610-Q10-QMay 7, 2026DEFA14ADEFA14AApr 29, 2026DEF 14ADEF 14AApr 29, 2026424B5424B5Mar 19, 20268-KMaterial AgreementMar 19, 202610-K10-KMar 19, 20268-KReg FD DisclosureFeb 2, 20268-KCompany UpdateJan 8, 2026424B5424B5Jan 8, 2026424B5424B5Jan 7, 20268-KReg FD Disclosure · Company UpdateJan 5, 20268-KExecutive ChangeJan 2, 202610-Q10-QNov 5, 20258-KExecutive Change · Shareholder VoteSep 3, 202510-Q10-QAug 7, 2025DEFA14ADEFA14AJul 11, 2025DEF 14ADEF 14AJul 11, 202510-Q10-QMay 6, 202510-K/A10-K/AApr 29, 202510-K10-KMar 28, 2025424B5424B5Mar 25, 20258-KCompany UpdateMar 25, 20258-KResults of Operations · Reg FD DisclosureMar 25, 20258-KExecutive ChangeFeb 3, 202510-Q10-QNov 14, 20248-KReg FD DisclosureNov 8, 2024SC 13GGENELUX CORPOct 25, 20248-KExecutive ChangeOct 3, 202410-Q10-QAug 14, 20248-KShareholder VoteAug 6, 20248-KReg FD DisclosureAug 1, 2024DEFA14ADEFA14AJun 14, 2024DEF 14ADEF 14AJun 14, 20248-KReg FD Disclosure · Company UpdateJun 5, 2024424B5424B5May 24, 20248-KMaterial Agreement · Reg FD DisclosureMay 24, 2024424B5424B5May 23, 202410-Q10-QMay 9, 20248-KReg FD DisclosureApr 9, 20248-KReg FD DisclosureApr 2, 202410-K10-KMar 29, 20248-KReg FD DisclosureFeb 5, 20248-KResults of Operations · Company UpdateFeb 2, 2024SC 13GSC 13GFeb 2, 20248-KReg FD DisclosureDec 12, 20238-KExecutive ChangeNov 24, 202310-Q10-QNov 14, 20238-KReg FD DisclosureOct 10, 20238-KExecutive Change · Shareholder VoteSep 14, 20238-KExecutive ChangeAug 28, 2023DEFA14ADEFA14AAug 24, 202310-Q10-QAug 14, 2023DEFA14ADEFA14AJul 20, 2023DEF 14ADEF 14AJul 20, 20238-KReg FD Disclosure · Company UpdateJul 19, 20238-KDelisting Notice · Executive ChangeJul 14, 2023S-1S-1Jun 28, 20238-KReg FD Disclosure · Company UpdateJun 27, 2023SC 13GSC 13GJun 20, 20238-KMaterial Agreement · Equity IssuanceJun 12, 20238-KExecutive ChangeJun 2, 202310-Q10-QMay 15, 202310-K/A10-K/AMay 1, 202310-K10-KMar 29, 20238-KExecutive Change · Bylaw AmendmentJan 30, 2023424B4424B4Jan 26, 2023S-1/AS-1/AJan 10, 2023S-1/AS-1/ADec 23, 2022S-1/AS-1/ANov 4, 2022S-1/AS-1/AOct 13, 2022S-1/AS-1/ASep 19, 2022S-1/AS-1/AAug 29, 2022S-1S-1Jun 24, 2022
Insider Activity
In the 90 days to Mar 25, 2026: 5 sold $43K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 25, 2026 | Smalling RalphHead of Regulatory | Sell | 240 | $2.51 | $602 |
| Mar 24, 2026 | Zindrick ThomasPresident and CEO | Sell | 3,582 | $2.42 | $9K |
| Mar 24, 2026 | Yu YongSVP, Clinical Development | Sell | 906 | $2.42 | $2K |
| Mar 24, 2026 | Cappello JosephChief Technical Officer | Sell | 906 | $2.42 | $2K |
| Mar 24, 2026 | Smalling RalphHead of Regulatory | Sell | 345 | $2.42 | $835 |
| Mar 2, 2026 | Thomas JohnDirector | Sell | 10,000 | $2.90 | $29K |
| Dec 5, 2025 | Smalling RalphHead of Regulatory | Sell | 165 | $4.69 | $774 |
| Dec 1, 2025 | Thomas JohnDirector | Sell | 10,000 | $5.00 | $50K |
| Nov 17, 2025 | Zindrick ThomasPresident and CEO | Sell | 4,509 | $5.37 | $24K |
| Nov 17, 2025 | Yu YongSVP, Clinical Development | Sell | 973 | $5.37 | $5K |
| Nov 17, 2025 | Cappello JosephChief Technical Officer | Sell | 973 | $5.37 | $5K |
| Nov 17, 2025 | Smalling RalphHead of Regulatory | Sell | 343 | $5.37 | $2K |
| Sep 3, 2025 | Smalling RalphHead of Regulatory | Sell | 580 | $3.36 | $2K |
| Aug 21, 2025 | Zindrick ThomasPresident and CEO | Sell | 12,673 | $3.33 | $42K |
| Aug 21, 2025 | Yu YongSVP, Clinical Development | Sell | 3,219 | $3.36 | $11K |
| Aug 21, 2025 | Cappello JosephChief Technical Officer | Sell | 1,463 | $3.36 | $5K |
| Aug 21, 2025 | Cappello JosephChief Technical Officer | Sell | 1,270 | $3.33 | $4K |
| Aug 21, 2025 | Smalling RalphHead of Regulatory | Sell | 1,244 | $3.36 | $4K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance